P48.17 Real-World Study of Patients With EGFR Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer Treated With First-Line Osimertinib

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are the recommended treatment for patients with advanced non-small cell lung cancer (NSCLC) with EGFR mutations (EGFRm). Osimertinib is a third-generation, irreversible, oral EGFR-TKI that potently and selectively inhibits both EGFRm and EGFR T790M, with demonstrated efficacy in NSCLC CNS metastases. Interim analysis of this real-world (rw) study reports the demographic and clinical characteristics, rw time to next treatment or death (rwTTNTD) and rw time to treatment discontinuation (rwTTD) of patients receiving osimertinib at first-line (1L) in the US.